

Antabio: treating severe & life-threatening infections

1



Nosocomial infections by carbapenem-resistant *Enterobacteriaceae* (CRE)

- Most urgent bacterial threat,
- 9,000+ CRE infections per year (US)
- High mortality rates

Chronic *Pseudomonas* infections in Cystic Fibrosis (CF) patients

- CF most common fatal genetic disease among Caucasians
 - 30,000 CF sufferers (US)
 - No cure

Fast moving programs on their way to the clinic

Strong expertise in metallo-enzyme inhibition



MBLi: Metallo β -lactamase inhibitors



Supported by **wellcome**trust



PBi: *Pseudomonas* Biofilm inhibitors



Supported by **wellcome**trust



Exploratory: leveraging Antabio's metallo-enzyme inhibition expertise



Supported by **bpi**france

Raising €15M to advance our first leads to the clinic

3



Our partners




Logos of partners: bpi france, wellcome trust, INNOVATION 2030 CONCOURS MONDIAL D'INNOVATION, RÉGION MIDI-PYRÉNÉES, Cancer-Bio-Santé CLUSTER, GALAXIE Club, SiCoval Le Sud-Est Toulousain, BioMedicalAlliance ASSOCIATION DES ENTREPRISES BIO-SANTÉ DE MIDI-PYRÉNÉES

Challenges & Opportunities of Antibacterial Discovery

Turning the "Bermuda" Triangle into a Magic Triangle

4



Opportunity!

- Simplified regulatory pathways now available
- Massive R&D incentives flowing into the area

But more needs to be done!

- Target investment to innovators
- Create stronger market incentives
- Further clarify the regulatory framework



Read the BEAM alliance position paper!

<http://beam-alliance.eu/>